首页> 美国卫生研究院文献>Neuro-Oncology >DIPG-06. RAPID ULTRA-DEEP SEQUENCING OF PEDIATRIC DIPG FROM CEREBROSPINAL FLUID USING A NOVEL HAND-HELD ELECTRONIC DNA ANALYSIS PLATFORM
【2h】

DIPG-06. RAPID ULTRA-DEEP SEQUENCING OF PEDIATRIC DIPG FROM CEREBROSPINAL FLUID USING A NOVEL HAND-HELD ELECTRONIC DNA ANALYSIS PLATFORM

机译:DIPG-06。使用新型手持式电子DNA分析平台从脑脊液中快速进行小儿DIPG测序

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

INTRODUCTION: Brain tumors release tumor DNA (tDNA) into cerebrospinal fluid (CSF), allowing for detection and serial monitoring of tumor-associated genetic mutations by CSF sampling. For midline and brainstem tumors such as diffuse intrinsic pontine glioma (DIPG), surgical biopsy poses possible severe neurological deficits. As such, liquid biopsy is needed. Current platforms for CSF tDNA analysis are limited by their requirement for assay development for each mutation (digital droplet PCR), or cost and timeliness (Illumina sequencing). We hypothesized that direct, electronic analysis of DNA with a novel hand-held platform (Oxford Nanopore) could provide real-time, ultra-deep (>1,000x reads) sequencing of DIPG CSF tDNA. METHODS: We performed amplicon-based PCR on DNA from normal brain (n=6), normal CSF (n=13), tumor brain (n=3), and tumor CSF (n=10) to amplify wildtype and mutant K27M K27M, and G328E genes from normal controls and pediatric patients with DIPG. We performed parallel barcoded sequencing of multiple samples run in duplicate or triplicate using NanoPore MinION technology and determined variant allele fraction (VAF) of each amplicon via an expeditious pipeline using MinKNOW, Albacore, MiniMap2, and Integrated Genome Browser. RESULTS: NanoPore sequenced 30 amplicons with average depth of 17,244 reads per amplicon in under 80 minutes. K27M VAF was 49.14% (S.D. 0.49) in tumor tissue and 13.63% (S.D. 0.35) in CSF. VAF was 10.42% (S. D. 1.11) for K27M and 7% (S.D. 0.46) for G328E in CSF. VAF were comparable to biopsy results by Illumina. Sensitivity and specificity of NanoPore were 100% and 98.8%, respectively, with p-values of < 0.05 for normal versus tumor samples. CONCLUSIONS: NanoPore MinION technology rapidly, reliably, and efficiently sequences tumor mutations in pooled tissue and CSF from patients with DIPG with outstanding sensitivity and specificity. NanoPore is more efficient, and cost and time effective than digital droplet PCR and Illumina.
机译:简介:脑肿瘤将肿瘤DNA(tDNA)释放到脑脊液(CSF)中,从而可以通过CSF采样检测和连续监测与肿瘤相关的基因突变。对于中线和脑干肿瘤,例如弥漫性桥脑神经胶质瘤(DIPG),手术活检可能会造成严重的神经功能缺损。因此,需要进行液体活检。当前用于CSF tDNA分析的平台受其对每种突变的测定开发(数字液滴PCR)或成本和及时性(Illumina测序)的要求所限制。我们假设使用新颖的手持平台(Oxford Nanopore)对DNA进行直接的电子分析可以提供DIPG CSF tDNA的实时,超深度(> 1,000次读取)测序。方法:我们对正常脑(n = 6),正常脑脊液(n = 13),肿瘤脑(n = 3)和肿瘤脑脊液(n = 10)的DNA进行了基于扩增子的PCR,以扩增野生型和突变型K27M K27M ,以及来自正常对照和DIPG患儿的G328E基因。我们使用NanoPore MinION技术对多个一式三份或一式三份的样品进行了平行条形码测序,并使用MinKNOW,Albacore,MiniMap2和Integrated Genome Browser通过快速管道确定了每个扩增子的变异等位基因片段(VAF)。结果:NanoPore在80分钟内对30个扩增子进行了测序,每个扩增子的平均深度为17,244个读数。肿瘤组织中的K27M VAF为49.14%(S.D. 0.49),而CSF为13.63%(S.D. 0.35)。 CSF中K27M的VAF为10.42%(S.D. 1.11),G328E为7%(S.D. 0.46)。 VAF与Illumina的活检结果相当。 NanoPore的敏感性和特异性分别为100%和98.8%,正常与肿瘤样品的p值<0.05。结论:NanoPore MinION技术可快速,可靠和高效地对DIPG患者合并组织和CSF中的肿瘤突变进行测序,具有出色的敏感性和特异性。与数字液滴PCR和Illumina相比,NanoPore效率更高,成本和时间更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号